[CAS NO. 1352792-74-5] Verinurad

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1352792-74-5]

Catalog

HY-16733

Brand

MCE

CAS

1352792-74-5

DESCRIPTION [1352792-74-5]

Overview

MDL	-
Molecular Weight	348.42
Molecular Formula	C20H16N2O2S
SMILES	CC(C)(SC1=C(C2=C3C=CC=CC3=C(C#N)C=C2)C=NC=C1)C(O)=O

For research use only. We do not sell to patients.

Summary

Verinurad (RDEA3170) is a highly potent and specific URAT1 inhibitor with an IC ₅₀ of 25 nM ^[1] .

IC50 & Target

IC50: 25 nM (URAT1) ^[1]

In Vitro

Verinurad inhibits the transport activity of human URAT1 in a dose-dependent manner, at high potency with an IC ₅₀ of 25 nM ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02317861	AstraZeneca\|Ardea Biosciences, Inc.	Gout and Asymptomatic Hyperuricemia	December 2014	Phase 1\|Phase 2
NCT01872832	Ardea Biosciences, Inc.	Gout	June 2013	Phase 1
NCT03118739	AstraZeneca	Hyperuricemia\|Albuminuria\|Type 2 Diabetes	May 18, 2017	Phase 2
NCT04256629	AstraZeneca\|Parexel	Healthy Volunteers (Intended Indication: Chronic Kidney Disease)	March 3, 2020	Phase 1
NCT01883167	Ardea Biosciences, Inc.	Healthy	June 2013	Phase 1
NCT02246673	Ardea Biosciences, Inc.	Gout	October 2014	Phase 2
NCT03316131	AstraZeneca\|Contract Research Organization: USA\|PAREXEL Early Phase Clinical Unit Baltimore\|PAREXEL Early Phase Clinical Unit-Los Angeles\|Clinical Laboratory: USA\|Harbor Hospital Laboratory\|GenX Laboratories Inc.\|Analytical Laboratory (Pharmacokinetic Sample Analysis): USA\|Covance Bioanalytical Services, LLC	Asymptomatic Hyperuricemia	October 25, 2017	Phase 2
NCT04327024	AstraZeneca	Heart Failure With Preserved Ejection Fraction (HFpEF)	May 19, 2020	Phase 2
NCT04024501	AstraZeneca	Chronic Kidney Disease	July 20, 2019	Phase 1
NCT02078219	AstraZeneca\|Ardea Biosciences, Inc.	Gout and Hyperuricemia	January 5, 2014	Phase 2
NCT03990363	AstraZeneca	Chronic Kidney Disease	July 23, 2019	Phase 2
NCT04550234	AstraZeneca\|Parexel	Chronic Kidney Disease	April 13, 2021	Phase 1
NCT04532918	AstraZeneca\|Parexel	Chronic Kidney Disease	September 10, 2020	Phase 1
NCT02219516	Ardea Biosciences, Inc.	Gout	August 1, 2014	Phase 1
NCT02279641	Ardea Biosciences, Inc.	Gout	November 1, 2014	Phase 1
NCT02336594	Ardea Biosciences, Inc.	Gout	November 2014	Phase 1
NCT01927198	Ardea Biosciences, Inc.	Gout	August 2013	Phase 2
NCT02498652	Ardea Biosciences, Inc.	Gout	July 28, 2015	Phase 2
NCT02608710	Ardea Biosciences, Inc.	Gout	November 2015	Phase 1
NCT03836599	AstraZeneca\|Parexel	Chronic Kidney Disease	January 16, 2019	Phase 1
NCT01910506	Ardea Biosciences, Inc.	Healthy	August 2013	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 287.01 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8701 mL	14.3505 mL	28.7010 mL
5 mM	0.5740 mL	2.8701 mL	5.7402 mL
10 mM	0.2870 mL	1.4350 mL	2.8701 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 2.5 mg/mL (7.18 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (7.18 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (7.18 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Tan PK, et al. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep. 2017 Apr 6;7(1):665.